Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotarem-enhanced MRA vs TOF MRA in Carotid and Vertebral Artery Disease
NCT01010932Phase 3Completed
- Sponsor
- Guerbet
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gadoterate meglumine in carotid artery disease, Vertebral artery disease (VAD), sponsored by Guerbet. Started Oct 2009; status: completed.
02
Drugs
gadoterate meglumine
03
Conditions
carotid artery diseaseVertebral artery disease (VAD)
Beyond the preview
Go deeper on NCT01010932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010932.